Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims align with the label on basic pharmacology (beta-blocker mechanism, sympathetic modulation) and on the not-for-performance-anxiety indication. However, numerous performance-anxiety–specific efficacy, timing, and dosing claims are not supported by the FDA-approved label, and several safety/contraindication nuances are either mischaracterized or omitted.
Category Scores
Accurate Statements
Propranolol is a beta-blocker.
PHARMACODYNAMICS (12)
Propranolol targets the sympathetic nervous system.
PHARMACODYNAMICS AND CLINICAL EFFECTS
Propranolol is not FDA-approved specifically for performance anxiety.
INDICATIONS AND USAGE (1)
Common side effects include fatigue.
ADVERSE REACTIONS (6)
Common side effects include low blood pressure.
ADVERSE REACTIONS (6)
Rare risks include slow heart rate.
ADVERSE REACTIONS (6)
Not for those bradycardia.
CONTRAINDICATIONS (4)
Not for those on certain meds like calcium channel blockers.
DRUG INTERACTIONS (7)
Propranolol reduces physical symptoms by blocking adrenaline's effects on the body.
PHARMACODYNAMICS (12)
Unsupported Statements
Propranolol reduces physical symptoms of performance anxiety like rapid heartbeat.
Absent in FDA label as an approved indication for performance anxiety; the label does not list performance anxiety as an approved indication.
Propranolol reduces physical symptoms of performance anxiety like trembling.
Absent in label; no performance-anxiety-specific indication.
Propranolol reduces physical symptoms of performance anxiety like sweating.
Absent in label; no performance-anxiety-specific indication.
Propranolol provides quick relief.
Not described as a quick-relief indication in the label; dosing/trequency for performance anxiety is not specified in the FDA label.
Propranolol provides relief without sedation.
Sedation is not listed as a label-provided outcome; not supported as a generalized claim in the label.
Propranolol is unlike benzodiazepines.
Label does not compare propranolol to benzodiazepines in terms of sedative properties.
A 2016 study found propranolol significantly lowered anxiety symptoms in performers compared to placebo.
Not described in FDA label; no study-level efficacy claim for performance contexts is in the label.
Musicians and actors report 70-80% symptom reduction in surveys.
Not described in FDA label; no survey-based efficacy data for performance contexts is in the label.
Propranolol is off-label for anxiety.
Off-label status may be discussed in practice, but the FDA label does not present performance-anxiety off-label claims as label content.
American Psychiatric Association guidelines endorse its situational use.
Label does not cite APA guidelines.
The typical dose is 10-40 mg orally.
The label does not specify a performance-anxiety–specific typical dose; this dosage range is not confirmed as a label statement for this indication.
The dose is 1 hour before performance.
Label does not provide a pre-event timing directive for performance anxiety.
Start with a low dose to check tolerance.
Label does not provide a general start-with-low-dose directive for this use.
Effects last 4-6 hours.
Label does not specify duration of effect for performance-anxiety use.
Avoid daily use to prevent rebound effects.
Label does not provide guidance about rebound effects for performance-anxiety use.
Avoid daily use to prevent dependency.
Label does not discuss dependency in this context.
Skip if pregnant.
Label contains pregnancy information but not the exact directive 'Skip if pregnant'; wording differs.
Skip if breastfeeding.
Label contains nursing information but not the exact directive 'Skip if breastfeeding'; wording differs.
Skip if contraindications like uncontrolled diabetes.
Label warnings/contraindications cover broader contexts; the exact phrasing is not present in the label.
Skip if peripheral artery disease.
Label contraindications do not specifically phrase this scenario in that wording.
For frequent anxiety, combine with therapy rather than relying solely on meds.
Label does not provide a therapy-combination recommendation for anxiety.
Always get medical advice to rule out interactions.
Label provides general cautions but not this exact advisory phrasing as a standalone recommendation.
Contradictions
Low
AI Statement
Not for those with heart conditions.
Label Reference
CONTRAINDICATIONS (4)
Important Omissions
Explicit contraindications for bronchospastic disease/asthma, cardiogenic shock, and AV block with first-degree or higher; and explicit boxed warnings related to these conditions.
Importance:
High
Monitoring recommendations and specific conditions requiring dose adjustments or avoidance (e.g., bronchospastic disease, bradycardia, hypotension) beyond general contraindications.
Importance:
Moderate
Storage and handling details (not always required for safety but part of label requirements).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Label-based risks (bradycardia, hypotension, bronchospasm risk in asthma) are addressed; many performance-anxiety–specific efficacy claims are unsubstantiated by the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Limit claims to label-supported indications, dosing, timing, and safety. Remove or clearly mark as off-label any performance-anxiety–specific efficacy statements and timing/dose guidance not present in the FDA label. Explicitly reference bronchospastic disease contraindication and other contraindications from the label; include monitoring guidance where appropriate.